表紙:呼吸器感染症治療の世界市場:規模、シェア、動向、予測(2022年~2028年)
市場調査レポート
商品コード
1084492

呼吸器感染症治療の世界市場:規模、シェア、動向、予測(2022年~2028年)

Respiratory Tract Infection Treatment Market - Size, Share, trends, and Forecast, 2022 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 157 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
呼吸器感染症治療の世界市場:規模、シェア、動向、予測(2022年~2028年)
出版日: 2022年05月25日
発行: Coherent Market Insights
ページ情報: 英文 157 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の呼吸器感染症の市場規模は、肺疾患の増加、高齢者の増加、小児における肺炎リスクの上昇、大気汚染の増加などによって促進されています。

当レポートでは、世界の呼吸器感染症治療市場を調査しており、市場の概要、市場規模や予測、動向、成長要因、抑制要因、医薬品クラス・適応症・流通チャネル・地域別の分析、および競合情勢などを提供しています。

目次

第1章 調査目的・前提条件

  • 調査目的
  • 仮定
  • 略語

第2章 市場概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場内訳:医薬品クラス別
    • 市場内訳:適応症別
    • 市場内訳:流通チャネル別
    • 市場内訳:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、および動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な発展
  • 規制シナリオ
  • パイプライン分析
  • 疫学
  • PEST分析
  • ポーターの分析

第4章 世界の呼吸器感染症治療市場:医薬品クラス別(2017年~2028年)

  • イントロダクション
  • 抗生物質
  • 非ステロイド性抗炎症薬(NSAIDS)
  • 咳抑制剤
  • 鼻充血除去薬
  • その他

第5章 世界の呼吸器感染症治療市場:適応症別(2017年~2028年)

  • イントロダクション
  • 上気道感染症
  • 下気道感染症

第6章 世界の呼吸器感染症治療市場:流通経路別(2017年~2028年)

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界の呼吸器感染症治療市場:地域別(2017年~2028年)

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • アフリカ
  • 中東

第8章 競合情勢

  • ヒートマップ分析
  • 企業プロファイル
    • Abbott Laboratories
    • AstraZeneca, Plc
    • Abbvie Inc.
    • Boehringer Ingelheim GmbH
    • Cipla Pharmaceutical Company
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Merck &Co.
    • Novartis AG
    • F. Hoffman La Roche Ltd
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
  • アナリストの見解

第9章 セクション

目次
Product Code: CMI2030

Respiratory tract infection is any infection in the nose, sinuses around the nose, throat (pharynx), voice box (larynx), and windpipe (trachea), airways (bronchi) or lungs, which may occur anytime, usually beginning with cold. This infection is usually caused by bacteria and viruses. Virus prone respiratory tract infection are easily transmitted and very contagious while bacterial infection can also be developed during the course of an upper respiratory tract infection. Respiratory tract infection is generally divided into two categories- upper respiratory tract infection (infection in nose, throat, and pharynx) and lower respiratory tract infection (infection below the larynx).

Market Dynamics

The global respiratory tract infection market is expected to witness lucrative growth due to factors such as increasing prevalence of lung diseases, surge in geriatric population, and rising risk of pneumonia in children. According to the World Health Organization (WHO), respiratory syncytial virus (RSV) is responsible for around 30 million lower respiratory tract infection cases in children worldwide. The prevalence of such viral diseases is expected to drive growth of the global market over the forecast period.

Increasing air pollution can severely affect respiratory health of children as well as adults. Various studies have shown effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies.

However, adverse effects of using NSAIDs and antibiotics on patients suffering from respiratory tract infection may hinder growth of the market. In 2015, the U.S. Food and Drug Administration (FDA) increased the warning labels on over-the-counter NSAIDs to highlight elevated risks for heart attack and stroke.

Key features of the study:

This report provides in-depth analysis of the respiratory tract infection treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global respiratory tract infection treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global respiratory tract infection treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for respiratory tract infection treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Respiratory Tract Infection Treatment Market, By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

Global Respiratory Tract Infection Treatment Market, By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

Global Respiratory Tract Infection Treatment Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Respiratory Tract Infection Treatment Market, By Region:

North America

By Country:

U.S.

Canada

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Europe

By Country:

U.K.

Germany

Italy

Spain

France

Russia

Rest of Europe

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Asia Pacific

By Country:

Australia

India

China

Japan

ASEAN

South Korea

Rest of Asia Pacific

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Latin America

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Middle East

By Country:

GCC

Israel

Rest of Middle East

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Africa

By Country:

South Africa

Central Africa

North Africa

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Company Profiles

Abbott Laboratories*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

AstraZeneca, Plc

Abbvie Inc.

Boehringer Ingelheim GmbH

Cipla Pharmaceutical Company

GlaxoSmithKline plc

Pfizer Inc.

Merck & Co.

Novartis AG

F. Hoffman La Roche Ltd

Sanofi

Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Pipeline Analysis
  • Epidemiology
  • PEST Analysis
  • PORTER'S Analysis

4. Global Respiratory Tract Infection Treatment Market, By Drug Class, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Antibiotics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Cough Suppressant
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nasal Decongestant
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Respiratory Tract Infection Treatment Market, By Disease Indication, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Upper Respiratory Tract Infection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Lower Respiratory Tract Infection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Respiratory Tract Infection Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Respiratory Tract Infection Treatment Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Abbott Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AstraZeneca, Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Abbvie Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Boehringer Ingelheim GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Cipla Pharmaceutical Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • F. Hoffman La Roche Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact